European Primary Care Cardiovascular Society

Heart Failure

Follow the news, literature, and elearning on new developments in the management of Heart Failure.

The 2021 ESC HF guidelines: What is new regarding patients with EF>40%?

3' education - Sep. 10, 2021 - Prof. Carolyn Lam, MD, PhD

Proven safety with ARNI in MI patients, but no definite difference for primary endpoint

5' education - May 27, 2021 - Prof. Marc Pfeffer, MD, PhD

The therapeutic options in HFrEF patients

3' education - Dec. 3, 2020 - Prof. Marc Pfeffer, MD, PhD

Reduced HF hospitalization in patients with iron deficiency after acute HF treated with ferric carboxymaltose

5' education - Dec. 3, 2020 - Prof. Piotr Ponikowski, MD, PhD

All three end points show benefit with another SLGT2 inhibitor in HFrEF

3' education - Sep. 16, 2020 - Milton Packer, MD

Screening for AF, HF and CAD in primary care

5' education - June 16, 2020 - Victor Zwartkruis

sGC stimulator has added value in worsening HFrEF patients

3' education - Apr. 10, 2020 - Prof. Paul Armstrong, MD - ACC 2020

ARNI seems to give CV benefit up to EF of about 60%, not only in HFrEF

3' education - Nov. 16, 2019 - Scott Solomon, Boston - AHA 2019, Philadelphia

Does HF have two physiologies that respond differently to treatment, or is it the same disease across the EF spectrum?

3' education - Nov. 18, 2019 - Lynne Stevenson, Nashville - AHA 2019, Philadelphia

SGLT2 inhibitor improves health status in HFrEF

3' education - Nov. 17, 2019 - Mikhail Kosiborod, Kansas City - AHA 2019, Philadelphia
EPCCS Annual CV Summit

Heart failure and comorbidities: kidney disease and cancer

5' education - Mar. 22, 2019 - Lisbon, Portugal - Peter van der Meer & Monika Hollander

SGLT2 inhibitor greatly reduced CV risk in HFrEF with or without diabetes

3' education - Sep. 16, 2019 - Paris, France - Prof. John McMurray
EPCCS Annual CV Summit

New diagnostic algorithm and therapeutic options in HF management

5' education - Mar. 22, 2019 - Lisbon, Portugal - Peter van der Meer & Monika Hollander

EPCCS

3' education - Feb. 8, 2019

HFpEF: What is it & size of the problem

10' education - Aug. 27, 2018 - Prof. Adriaan Voors - Groningen, The Netherlands

Complexities of managing heart failure

10' education - Mar. 16, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Clare Taylor, Dr. Nuria Farré and Dr. Frans Rutten
##SCROLLER_ITEMS_FULL_TITLE##

Heart failure diagnosis and management varies substantially across European countries

10' education - May 25, 2017
##SCROLLER_ITEMS_FULL_TITLE##

Heart failure diagnosis and management

10' education - Dec. 9, 2015 - EPCCS 2015 - Prague

The 2021 ESC HF guidelines: What is new regarding patients with EF>40%?

3' education - Sep. 10, 2021 - Prof. Carolyn Lam, MD, PhD
Prof. Carolyn Lam discusses the major changes in the 2021 ESC/HFA heart failure guidelines regarding diagnosis and treatment of patients with ejection fraction above 40%.

ESC 2021 Prof. Carolyn Lam discusses the major changes in the 2021 ESC/HFA heart failure guidelines regarding diagnosis and treatment of patients with ejection fraction above 40%.

Composite of CV death or HF hospitalizations reduced by SGLT2i in HFpEF

News - Sep. 8, 2021

ESC 2021 The EMPEROR-Preserved trial showed that empagliflozin significantly reduced the risk of the primary composite endpoint of CV death or HF hospitalization by 21%, compared to placebo, in patients with HF and LVEF >40%, with and without T2DM.

What are the changes in the 2021 ESC/HFA heart failure guidelines?

News - Sep. 8, 2021

ESC 2021 New concepts in the 2021 HF guidelines include a simplified treatment algorithm for HFrEF, change of the HFmrEF term to heart failure with mildly reduced ejection fraction and a treatment algorithm for HFrEF according to phenotypes.

SGLT2i reduces HF hospitalizations across broad range of ejection fractions

News - Sep. 8, 2021

ESC 2021 EMPEROR-Pooled was a pooled analysis of the data from EMPEROR-Reduced and EMPEROR-Preserved and showed that empagliflozin, compared to placebo, reduced HF hospitalizations by ~30% in patients with HF across a range of LVEF from <25% to <65%.

Association between incident HF and T2DM-related microvascular disease

Literature - July 27, 2021 - Kaze AD, et al. - J Am Heart Assoc. 2021

Microvascular disease (MVD) was associated with the development of HF in adults with T2DM, independently of traditional risk factors including CAD.

Primary endpoint met in phase III trial with SGLT2i in HFpEF

News - July 6, 2021

EMPEROR-Preserved met its primary endpoint and showed a significant risk reduction with empagliflozin for the composite endpoint of time to first event of CV death or HF hospitalization compared to placebo in adults with HFpEF, with or without T2DM.

Nonsteroidal MRA reduces CV and kidney outcomes in CKD and T2DM irrespective of HF status

News - July 1, 2021

ESC HF 2021 A subanalysis of FIDELIO-DKD showed that finerenone lowered CV and kidney outcomes compared to placebo in patients with T2DM and CKD irrespective of pre-existing HF status.

Low testing rates for iron deficiency in HF in registry study

News - July 1, 2021

ESC HF 2021 In a nation-wide HF registry, screening for iron deficiency was performed in only 27% of patients. 19% Of patients with iron deficiency received treatment with ferric carboxymaltose.

Ferric carboxymaltose results in improved QoL in iron-deficient patients, stabilized after acute HF

Literature - June 23, 2021 - Jankowska EA et al. - Eur Heart J. 2021

Treatment with IV ferric carboxymaltose in patients with iron deficiency who had stabilized after acute HF led to greater improvements in health-related quality of life from week 4 to week 24 after discharge, compared to placebo.

SGLT2i approved by EC for treatment of HFrEF

News - June 22, 2021

The European Commission has extended the indication for empagliflozin and empagliflozin is now also approved for the treatment of adults with HFrEF.

Comparing outcomes of ablation-based rhythm control vs. rate control in AF with HF

News - May 27, 2021

ACC 2021 Ablation-based rhythm control and rate control showed no statistically significant differences in the RAFT-AF trial for the primary outcome of all-cause mortality and HF events in patients with HF and high burden AF.

Improved physical function by physical rehabilitation intervention in older patients with ADHF

News - May 27, 2021

ACC 2021 REHAB-HF showed that individualized physical rehabilitation intervention, compared to usual care, resulted in significant improvements in physical function, frailty status, quality of life, and depression in older patients with ADHF.